Received May 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | — | — |
itching at the injection site (arm); This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site itching in a adolescent female patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis. Concurrent medical conditions included latex allergy (latex sensitivity). On an unknown date, the patient received Menveo (unknown arm). On an unknown date, an unknown time after receiving Menveo, the patient experienced injection site itching (Verbatim: itching at the injection site (arm)). The outcome of the injection site itching was resolved. It was unknown if the reporter considered the injection site itching to be related to Menveo. It was unknown if the company considered the injection site itching to be related to Menveo. Additional Information: GSK receipt date 08-MAY-2026 The mother/reporter did not have a record the lot number or expiration date. The mother stated that her daughter received a meningitis vaccine, which she believed was MENVEO, when she was maybe 13 or 16 years old. At that time she had a (known) mild sensitivity to latex and due to that she had a mild reaction of itching at the injection site unspecified arm. The itching resolved. The reporter did not remember/know how long it took for the itching to resolve. The batch number was not provided upon follow- up with the reporter.
Latex allergy (latex sensitivity)